共 277 条
[1]
Welch JS(2012)The origin and evolution of mutations in acute myeloid leukemia Cell 150 264-278
[2]
Ley TJ(2015)Current approaches in the treatment of relapsed and refractory acute myeloid leukemia J Clin Med 4 665-695
[3]
Link DC(2009)Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials JAMA 301 2349-2361
[4]
Miller CA(2011)Evaluation of current cancer immunotherapy: hemato-oncology Cancer J 17 309-324
[5]
Larson DE(2014)Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation Biol Blood Marrow Transpl 20 154-163
[6]
Koboldt DC(2015)Immunotherapy for acute myeloid leukemia Semin Hematol 52 207-214
[7]
Ramos NR(2009)Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia Blood 113 2245-2255
[8]
Mo CC(2010)Mutation or loss of Wilms’ tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination J Transl Med 8 5-6548
[9]
Karp JE(2009)A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS Blood 113 6541-375
[10]
Hourigan CS(2014)Wilms’ tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses Br J Haematol 164 366-179